Hospital
Mclaren Thumb Region
Mclaren Thumb Region was paid $4.97M by Medicaid between Jan 2018 and Dec 2024, across 137 billing codes. Its largest line is 99284, emergency room visit (serious) — 22% of everything it billed.
33Billing provider infoMCLAREN THUMB REGION
BAD AXE, MI 48413
BAD AXE, MI 48413
33aNPI1518991744assigned 07/11/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$4.97M
24GClaims163,002
24DCodes billed137
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Medicare Defined Swing Bed Hospital Unit providers in Michigan
Rank by total paid#6 of 8
Median peer was paid$5.78M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BARANSKI, KENNETH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,844 | $526K | |
| 2019 | 22,939 | $481K | |
| 2020 | 19,829 | $503K | |
| 2021 | 25,298 | $824K | |
| 2022 | 27,784 | $996K | |
| 2023 | 27,288 | $917K | |
| 2024incomplete | 19,020 | $722K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 5,458 | 4,970 | $1.08M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 18% | 6,547 | 6,115 | $910K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 2,343 | 2,203 | $853K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 6.3% | 4,677 | 3,807 | $311K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.1% | 2,757 | 2,582 | $304K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.9% | 1,735 | 1,027 | $196K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 3.7% | 1,202 | 460 | $182K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 1,743 | 1,636 | $130K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.2% | 560 | 545 | $111K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 1,892 | 1,690 | $80K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 2,240 | 1,975 | $79K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 1,830 | 1,772 | $70K |
125 more codes
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 461 | $49K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,673 | $48K |
| 71045 | Radiologic examination, chest; single view | <1% | 935 | $42K |
| 86886 | <1% | 1,523 | $34K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 650 | $30K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 113 | $29K |
| 80061 | Lipid panel | <1% | 2,631 | $26K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,746 | $25K |
| 62323 | <1% | 64 | $25K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 415 | $24K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,237 | $23K |
| 80053 | Comprehensive metabolic panel | <1% | 9,855 | $22K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 174 | $20K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 694 | $19K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 11,228 | $19K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 101 | $17K |
| 73630 | <1% | 691 | $15K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 203 | $12K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 823 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 12,400 | $11K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 775 | $11K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 822 | $10K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 544 | $10K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,869 | $8K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,804 | $8K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 43 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,845 | $5K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 227 | $5K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 336 | $5K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 128 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,422 | $4K |
| 84439 | <1% | 1,047 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,797 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,316 | $4K |
| 87634 | <1% | 75 | $3K | |
| 85027 | <1% | 1,890 | $3K | |
| 01936 | <1% | 62 | $3K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 86 | $3K |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | <1% | 13 | $3K |
| 76830 | Ultrasound, transvaginal | <1% | 57 | $3K |
| 87070 | <1% | 848 | $3K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 71 | $2K |
| 87660 | <1% | 296 | $2K | |
| 87480 | <1% | 295 | $2K | |
| 87510 | <1% | 295 | $2K | |
| 83735 | <1% | 3,968 | $2K | |
| 88142 | <1% | 202 | $2K | |
| 82607 | <1% | 279 | $2K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 28 | $2K |
| 80305 | <1% | 1,173 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 173 | $2K |
| 01992 | <1% | 89 | $2K | |
| 97162 | <1% | 26 | $2K | |
| 84702 | <1% | 455 | $2K | |
| 73130 | <1% | 78 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 185 | $1K |
| 73562 | <1% | 50 | $991.38 | |
| 85610 | <1% | 2,329 | $865.72 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 45 | $863.80 |
| 81001 | <1% | 2,552 | $831.95 | |
| 86900 | <1% | 1,710 | $822.07 | |
| 81003 | <1% | 2,396 | $719.70 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 42 | $657.97 |
| 73030 | <1% | 25 | $654.42 | |
| 84100 | <1% | 2,386 | $646.92 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 527 | $644.82 |
| 87186 | <1% | 254 | $617.95 | |
| 87340 | <1% | 225 | $612.37 | |
| 86762 | <1% | 158 | $589.02 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 104 | $550.44 |
| 72110 | <1% | 12 | $530.89 | |
| 73610 | <1% | 26 | $521.56 | |
| 87503 | <1% | 77 | $511.87 | |
| 86592 | <1% | 186 | $483.51 | |
| 87653 | <1% | 26 | $412.33 | |
| 83880 | <1% | 471 | $404.26 | |
| 86901 | <1% | 1,733 | $378.92 | |
| 83690 | <1% | 2,382 | $352.93 | |
| 86140 | <1% | 400 | $341.84 | |
| 85730 | <1% | 1,288 | $326.53 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 24 | $317.44 |
| 87081 | <1% | 68 | $301.30 | |
| 83605 | <1% | 2,433 | $286.00 | |
| 81025 | <1% | 1,833 | $284.16 | |
| 83540 | <1% | 81 | $261.99 | |
| 82550 | <1% | 1,381 | $259.59 | |
| 82150 | <1% | 1,205 | $173.10 | |
| 84484 | <1% | 2,083 | $127.47 | |
| 82565 | <1% | 43 | $107.19 | |
| 87077 | <1% | 13 | $60.30 | |
| 81015 | <1% | 334 | $54.71 | |
| 82950 | <1% | 18 | $37.90 | |
| 84520 | <1% | 16 | $35.57 | |
| 87040 | <1% | 53 | $22.20 | |
| 83516 | <1% | 21 | $17.60 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,604 | $10.15 |
| 85018 | <1% | 12 | $7.99 | |
| 85014 | <1% | 12 | $7.99 | |
| 85379 | <1% | 46 | $7.68 | |
| 85651 | <1% | 12 | $6.81 | |
| 85652 | <1% | 18 | $6.42 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,564 | $3.52 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,824 | $3.14 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,583 | $2.22 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,712 | $2.20 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,862 | $1.40 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,673 | $0.01 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 262 | $0.00 |
| A9270 | Non-covered item or service | 0% | 2,361 | $0.00 |
| J3490 | Unclassified drugs | 0% | 2,380 | $0.00 |
| 84703 | 0% | 13 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 279 | $0.00 |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 44 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 17 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 40 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 13 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 12 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 23 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 822 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 273 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 191 | $0.00 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 12 | $0.00 |
| 82948 | 0% | 23 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 71 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBARANSKI, KENNETH (VP/CFO)
| Provider | Location | Paid |
|---|---|---|
| Mclaren Caro Region | Caro, MI | $5.78M |
| Mclaren Thumb Region | Bad Axe, MI | $1.57M |
| General John J Pershing Memorial Hospital Association | Brookfield, MO | $913K |
| Hills & Dales General Hospital, INC. | Kingston, MI | $603K |
| General John J Pershing Memorial Hospital Association | Brookfield, MO | $588K |
| Hills & Dales General Hospital, INC. | Cass City, MI | $491K |
| Hills & Dales General Hospital, INC. | Cass City, MI | $478K |
| Mclaren Thumb Region | Bad Axe, MI | $385K |
| General John J Pershing Memorial Hospital Association | Brookfield, MO | $251K |
| Hills & Dales General Hospital, INC. | Cass City, MI | $231K |
| Mclaren Thumb Region | Bad Axe, MI | $207K |
| Mclaren Thumb Region | Bad Axe, MI | $154K |
| Hills & Dales General Hospital, INC. | Ubly, MI | $146K |
| Mclaren Thumb Region | Ubly, MI | $120K |
| Mclaren Caro Region | Caro, MI | $99K |
| General John J Pershing Memorial Hospital Association | Brookfield, MO | $86K |
| Mclaren Caro Region | Caro, MI | $75K |
| Mclaren Thumb Region | Bad Axe, MI | $71K |
| Mclaren Caro Region | Caro, MI | $51K |
| Mclaren Caro Region | Vassar, MI | $49K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.